ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 42

The Prevalence of Ankylosing Spondylitis in Sweden – a Nationwide Register Study

Sofia Exarchou1, Ulf Lindström2, Johan Askling3, Jonas Eriksson4, Helena Forsblad-d'Elia2, Lars Erik Kristensen5, Martin Neovius4, Carl Turesson1 and Lennart T. Jacobsson2, 1Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 3Clinical Epidemiology Unit, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 4Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 5Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More

Session Type: Abstract Submissions (ACR)

Background/Purpose: Reported Ankylosing Spondylitis (AS) prevalence estimates vary considerably, and there is a lack of nationwide estimates. Previous studies by our group support the validity of WHO International Classification of Disease codes (ICD-codes) for AS in the Swedish National Patient Register (NPR) and indicate that the mean diagnostic delay is about 10 years. This study aims to describe the national prevalence of diagnosed AS in Sweden, based on data from the NPR, overall as well as stratified by age and sex, and to explore treatment, geographical variation and socio-economic factors in the Swedish AS population.

Methods: All patients given a diagnosis of AS according to ICD-codes in the NPR between 1967 and 2009 were identified. Statistics Sweden, the Swedish biologic register (ARTIS) and the national drug prescription register were used to retrieve data on demographics, drug exposure, level of education and vital status. Our case definition required at least one registered AS diagnosis in inpatient care 1967- present) or specialized outpatient care (2001- present), not including primary care and private practice. Results are presented for individuals 16-64 years old in 2009.

Results: On 31 December 2009, Sweden had a population of approximately 9.3 millions, of which 64% were in the age group 16-64 years old and 50.8% were men. Between 1967 and 2009, 20 044 patients with at least one health care registration in the NPR with a diagnosis of AS were identified. Of those, 11 030 were 16-64 years old, alive and living in Sweden on Dec 31, 2009. The overall prevalence of AS in this age group in 2009 was thus 0.18%. The prevalence increased linearly with age up to the age of 55 years, after which it leveled off. For all investigated age groups combined, men had a higher prevalence compared to women (0.23% vs 0.14%). During 2009, NSAIDs, DMARDs, corticosteroids and TNF-inhibitors had been prescribed to the AS patients in 53.4%, 20.4%, 11.7% and 14.2% respectively. Prevalence estimates by health care region revealed the highest age-/sex-standardized prevalence in the Northern Health Care Region (0.24%; 95% CI 0.23-0.25). The association between level of education and AS prevalence was explored only in those > 30 years old on Dec 31, 2009. The age-/sex-standardized prevalence of AS was lowest among those with > 12 years of education (0.20%; 95% CI 0.19-0.21), while somewhat higher prevalences were observed in the other two strata with a shorter formal education (≤ 9 years and 10-12 years) (0.24%; 95% CI 0.22-0.25 and 0.24%; 95% CI 0.23-0.24).  

Conclusion: This nationwide, register-based prevalence estimate of AS in Sweden offers a unique opportunity to better understand the burden of AS to the healthcare system. Moreover, geographic and socio-economic differences in prevalence estimates suggest that genetic and possibly also environmental factors may be important for disease development and detection.


Disclosure:

S. Exarchou,
None;

U. Lindström,
None;

J. Askling,
None;

J. Eriksson,
None;

H. Forsblad-d’Elia,
None;

L. E. Kristensen,
None;

M. Neovius,
None;

C. Turesson,
None;

L. T. Jacobsson,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-ankylosing-spondylitis-in-sweden-a-nationwide-register-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.